Neod001 Medicine 09 January 2018 Extended indication Primary systemic amyloidosis (AL amyloïdose). Therapeutic value No judgement Total cost Registration phase Withdrawn Product Active substance Neod001 Domain Metabolism and Endocrinology Reason of inclusion Main indication Metabolic diseases Extended indication Primary systemic amyloidosis (AL amyloïdose). Current proprietary name Already available biosimilars / generics Proprietary name Manufacturer Prothena Portfolio holder Mechanism of action Unknown Route of administration Intravenous Therapeutical formulation Intravenous drip Budgetting framework Intermural (MSZ) Centre of expertise Additional remarks Monoklonaal antilichaam gericht tegen amyloïden Registration Registration route Centralised (EMA) Type of trajectory Unknown Particularity New medicine ATMP Unknown Submission date Expected Registration 2020 Orphan drug Yes Registration phase Withdrawn Reimbursement Medicine sluice Additional remarks Ontwikkeling is gestopt per april 2018. Primaire eindpunten zijn niet gehaald. Therapeutic value Current treatment options Therapeutic value No judgement This assessment does not indicate any potential inclusion in the package. Substantiation Duration of treatment Frequency of administration Dosage per administration References Additional remarks Expected patient volume per year Patient volume 87 - 218 Market share is generally not included unless otherwise stated. Maximum patient volume for sluice References Amyloidose Nederland Additional remarks De geschatte incidentie ligt tussen de 5,1 en 12,8 per miljoen inwoners per jaar, dit betekent voor Nederland dus 87-218 patiënten per jaar. Expected cost per patient per year Cost References Additional remarks Potential total cost per year Total cost Total cost for sluice Additional remarks Off label use Off label use Unknown Indications off label use References Additional remarks Indication extension Indication extensions Unknown Indication extensions References Additional remarks Other information Additional remarks